Avelumab – novinka v léčbě pacientů s metastazujícím karcinomem z Merkelových buněk

06/2018

MUDr. Viera Bajčiová, CSc.

Klinika dětské onkologie Fakultní nemocnice Brno

SUMMARY

Merkel cell carcinoma (MCC) is a rare aggressive skin neuroendocrine cancer, metastatic disease is associated with poor prognosis and overal survival. The efficacy of avelumab in the JAVELIN Merkel 200 registration study in metastatic MCC refractory to chemotherapy patients and also in untreated chemotherapy naive patients with MCC resulted in its approval by the Food and Drug Administration (FDA) in the US in March 2017 and subsequently in Europe in September 2017. The administration of avelumab in advanced MCCs on both first and subsequent treatment lines has shown prolongation of the interval in both progression and overall survival and good safety profile with manageable side effects.

KEY WORDS

Merkel cell carcinoma, immunotherapy, avelumab